{"id":"W4402704908","doi":"10.1016/j.annonc.2024.08.1741","title":"1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EMD Serono; Genentech; Astellas Pharma; Moderna; Jounce Therapeutics; SK Life Science; Incyte; MacroGenics; Aptitude Health; AbbVie; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Antibody-drug conjugate; Conjugate; Internal medicine; Antibody; Cancer; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001046701,0.001018157,0.001382263,0.0003250554,0.0004219993,0.001129282,0.0004374628,0.001234314,0.003720786],"category_scores_gemma":[0.0007721407,0.0006507505,0.001187277,0.0003361116,0.001101772,0.0007759543,0.0002399624,0.003249682,0.001327852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008240191,"about_ca_system_score_gemma":0.001123721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001954048,"about_ca_topic_score_gemma":0.002338112,"domain_scores_codex":[0.999619,0.0001653365,0.00001435133,0.00007274983,0.00002989385,0.00009872853],"domain_scores_gemma":[0.9995188,0.00007840584,0.00005259423,0.00005019763,0.00003422803,0.0002658766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7947448,0.08490442,0.01126633,0.0004420787,0.001041951,0.000571809,0.0002771914,0.001950414,0.04190728,0.0002869748,0.002964323,0.05964245],"study_design_scores_gemma":[0.1204311,0.8461386,0.0187443,0.00002072891,0.000612562,0.0004561791,0.00009894191,0.001330652,0.007893199,0.0001294299,0.004091317,0.00005298111],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941452,0.001424598,0.0004101374,0.0001949012,0.0001497181,0.0006927829,0.001041327,0.00006305289,0.001878354],"genre_scores_gemma":[0.9933892,0.0009195973,0.0004402556,0.0003267832,0.0001116165,0.0002935289,0.001415114,0.00001705323,0.003086593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003720786,"threshold_uncertainty_score":0.0124473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05999168936279459,"score_gpt":0.4197392316218485,"score_spread":0.3597475422590539,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}